AMA Recognizes ArcheMedX’s COVID-19 Report on Virtual Tech in Clinical Trials for Excellence
Today, ArcheMedX announced that its 2020 industry report, “COVID-19’s Impact on Virtual Tech in Clinical Trials, was honored with a prestigious American Marketing Association (AMA) award.
Every year, the AMA honors hundreds of stand-out marketers through awards programs presented by the AMA Foundation, local professional chapters, and academic special interest groups. The awards recognize individuals and companies for remarkable, effective campaigns from the past year.
COVID-19 broadly impacted the world around us and created significant challenges across numerous industries. For those working in clinical research, an industry notoriously slow to change and adopt digital tools, the pandemic wreaked havoc on clinical trials that had been extremely reliant on face-to-face interaction.
The ArcheMedX team crafted the report to serve the industry when it was struggling to overcome the limitations imposed by COVID-19. After carefully planning and deploying a survey to clinical operations professionals across the life sciences sector, the team poured over the data.
Those data revealed the biggest challenges the industry, and particularly ArcheMedX’s clients, were facing as they tried to keep life-saving research going.
In a comprehensive report, ArcheMedX shared brand-new insights into how 89% of clinical trial leaders in pharmaceuticals, biotech, and clinical research organizations planned to accelerate the use of virtual solutions and digital tools to advance clinical research in the current and post-pandemic environment.
“Our industry was reeling last year due to the pandemic, but life-saving research has to keep going. While research into COVID-19 therapies and vaccines found a way forward, thousands of other clinical trials stalled while millions of people still suffered from their own life altering diseases that on-going clinical research could treat. We launched this project to discover and share insights with clinical operations leaders on how they could adapt quickly with digital and virtual technology,” said Molly Maple Bryant, Head of Marketing at ArcheMedX.
The detailed report, and its accompanying content, outreach, and data were selected to receive the best campaign award in the Pandemic Pivot category – an award recognizing the shift that many teams had to make in the face of COVID-19. The Charleston, SC chapter of the AMA presented the award at their annual Spark! Awards celebration.
“This award is a well deserved recognition of the innovative and creative spirit permeating across the ArcheMedX team throughout the pandemic. Despite persistent challenges, the team consistently finds ways to make a positive impact in the work and lives of our life science and healthcare partners,” shared Joel Selzer, Co-Founder & CEO of ArcheMedX.
The COVID-19’s Impact on Virtual Tech in Clinical Trials is available for download now, and a refreshed set of data and insights is planned for late 2021.
About ArcheMedX:
ArcheMedX helps companies across the life sciences and healthcare industries to better equip, evaluate, and predict team and clinician performance, in order to accelerate the development and adoption of new clinical treatments and best practices.
Ready by ArcheMedX is an industry leading solution that predicts and improves clinical trial performance. The platform applies behavioral science to enhance how trial team members and site personnel will apply knowledge and skills in real-world scenarios. Ready then analyzes unique behavioral indicators to reveal areas of trial readiness and potential risk.
To learn more about our readiness solutions across clinical operations, commercial programs, and medical education, visit www.archemedx.com or follow ArcheMedX on LinkedIn.
